231 related articles for article (PubMed ID: 36566436)
41. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.
Almeida MR; Macedo B; Cardoso I; Alves I; Valencia G; Arsequell G; Planas A; Saraiva MJ
Biochem J; 2004 Jul; 381(Pt 2):351-6. PubMed ID: 15080795
[TBL] [Abstract][Full Text] [Related]
42. Carrier-mediated thyroid hormone transport into placenta by placental transthyretin.
Landers KA; McKinnon BD; Li H; Subramaniam VN; Mortimer RH; Richard K
J Clin Endocrinol Metab; 2009 Jul; 94(7):2610-6. PubMed ID: 19401362
[TBL] [Abstract][Full Text] [Related]
43. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of a panel of in vitro methods for assessing thyroid receptor β and transthyretin transporter disrupting activities.
Collet B; Simon E; van der Linden S; El Abdellaoui N; Naderman M; Man HY; Middelhof I; van der Burg B; Besselink H; Brouwer A
Reprod Toxicol; 2020 Sep; 96():432-444. PubMed ID: 31077750
[TBL] [Abstract][Full Text] [Related]
45. Rafoxanide, a salicylanilide anthelmintic, interacts with human plasma protein transthyretin.
Yokoyama T; Mizuguchi M; Nabeshima Y; Nakagawa Y; Okada T; Toyooka N; Kusaka K
FEBS J; 2023 Nov; 290(21):5158-5170. PubMed ID: 37522420
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.
Yokoyama T; Mizuguchi M
Biol Pharm Bull; 2018; 41(7):979-984. PubMed ID: 29962408
[TBL] [Abstract][Full Text] [Related]
47. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state.
Petrassi HM; Johnson SM; Purkey HE; Chiang KP; Walkup T; Jiang X; Powers ET; Kelly JW
J Am Chem Soc; 2005 May; 127(18):6662-71. PubMed ID: 15869287
[TBL] [Abstract][Full Text] [Related]
48. Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein transthyretin.
Weiss JM; Andersson PL; Lamoree MH; Leonards PE; van Leeuwen SP; Hamers T
Toxicol Sci; 2009 Jun; 109(2):206-16. PubMed ID: 19293372
[TBL] [Abstract][Full Text] [Related]
49. Kinetic stabilization of an oligomeric protein by a single ligand binding event.
Wiseman RL; Johnson SM; Kelker MS; Foss T; Wilson IA; Kelly JW
J Am Chem Soc; 2005 Apr; 127(15):5540-51. PubMed ID: 15826192
[TBL] [Abstract][Full Text] [Related]
50. Interspecies Variation between Fish and Human Transthyretins in Their Binding of Thyroid-Disrupting Chemicals.
Zhang J; Grundström C; Brännström K; Iakovleva I; Lindberg M; Olofsson A; Andersson PL; Sauer-Eriksson AE
Environ Sci Technol; 2018 Oct; 52(20):11865-11874. PubMed ID: 30226982
[TBL] [Abstract][Full Text] [Related]
51. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis.
Schreiber G
J Endocrinol; 2002 Oct; 175(1):61-73. PubMed ID: 12379491
[TBL] [Abstract][Full Text] [Related]
52. Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
Yokoyama T; Mizuguchi M
J Med Chem; 2019 Feb; 62(4):2076-2082. PubMed ID: 30688456
[TBL] [Abstract][Full Text] [Related]
53. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and structural analysis of the N-terminal domain of the thyroid hormone-binding protein transthyretin.
Wilce JA; Daly NL; Craik DJ
Clin Chem Lab Med; 2002 Dec; 40(12):1221-8. PubMed ID: 12553422
[TBL] [Abstract][Full Text] [Related]
55. Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.
Ciccone L; Nencetti S; Tonali N; Fruchart-Gaillard C; Shepard W; Nuti E; Camodeca C; Rossello A; Orlandini E
Bioorg Med Chem; 2020 Sep; 28(18):115673. PubMed ID: 32828431
[TBL] [Abstract][Full Text] [Related]
56. Transthyretin regulates thyroid hormone levels in the choroid plexus, but not in the brain parenchyma: study in a transthyretin-null mouse model.
Palha JA; Fernandes R; de Escobar GM; Episkopou V; Gottesman M; Saraiva MJ
Endocrinology; 2000 Sep; 141(9):3267-72. PubMed ID: 10965897
[TBL] [Abstract][Full Text] [Related]
57. Transport of the Thyroid Hormone Carrier Protein Transthyretin into Human Epidermoid Cells.
Fong VH; Wong S; Jintaridhi P; Vieira A
Endocr Res; 2020; 45(2):131-136. PubMed ID: 31762320
[No Abstract] [Full Text] [Related]
58. Cell and molecular biology of transthyretin and thyroid hormones.
Richardson SJ
Int Rev Cytol; 2007; 258():137-93. PubMed ID: 17338921
[TBL] [Abstract][Full Text] [Related]
59. Transthyretin microheterogeneity and molecular interactions: implications for amyloid formation.
Landreh M; Ostberg LJ; Pettersson TM; Jörnvall H
Biomol Concepts; 2014 Jun; 5(3):257-64. PubMed ID: 25372757
[TBL] [Abstract][Full Text] [Related]
60. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
